drugset
drugset / Trial / NCT04853134

Proxalutamide Treatment for COVID-19 Female Outpatients

NCT04853134 ↗

Phase 3 Withdrawn Applied Biology, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection

Timeline

Start
2020-11-01
Primary completion
2021-12-01
Completion
2021-12-01

Outcome

Outcome not reported

Stopped: “This study was combined with another study”

Drugs

EvaluationDrugModalityDoseRoute
Comparator PRUXELUTAMIDE Small molecule 200 mg —

Indications

COVID-19